Ameriprise’s CASI Pharmaceuticals CASI Stock Holding History

Ameriprise’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,000	Closed	-$8K	–	3901
2022 Q1	$8K	Hold	1,000	–	–	﹤0.01%	3919
2021 Q4	$8K	Hold	1,000	–	–	﹤0.01%	3946
2021 Q3	$12K	Hold	1,000	–	–	﹤0.01%	3843
2021 Q2	$16K	Sell	1,000 -700	-41%	-$11.8K	﹤0.01%	3873
2021 Q1	$41K	Hold	1,700	–	–	﹤0.01%	3807
2020 Q4	$50K	Hold	1,700	–	–	﹤0.01%	3723
2020 Q3	$26K	Sell	1,700 -507	-23%	-$9.55K	﹤0.01%	3696
2020 Q2	$55K	Buy	2,207 +1	+0%	+$22	﹤0.01%	3614
2020 Q1	$45K	Sell	2,206 -304	-12%	-$7.25K	﹤0.01%	3587
2019 Q4	$78K	Sell	2,510 -595	-19%	-$19.3K	﹤0.01%	3650
2019 Q3	$104K	Sell	3,105 -600	-16%	-$19.3K	﹤0.01%	3630
2019 Q2	$119K	Sell	3,705 -985	-21%	-$31.4K	﹤0.01%	3648
2019 Q1	$135K	Sell	4,690 -1,120	-19%	-$39K	﹤0.01%	3609
2018 Q4	$234K	Sell	5,810 -246	-4%	-$9.32K	﹤0.01%	3408
2018 Q3	$283K	Buy	+6,056	New	+$423K	﹤0.01%	3457

Other funds holding CASI

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return

WSC

Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Ameriprise's CASI Position: Q2 2022 in Review

Ameriprise sold out of CASI Pharmaceuticals (CASI) in Q2 2022, closing a stake of 1,000 shares — an estimated $8K sold.

Ameriprise first reported a position in CASI in Q3 2018 and held it in 15 quarters. The position peaked at $283K in Q3 2018. 24 funds tracked by Wall St. Rank hold CASI as of Q2 2022.

Ameriprise reported no remaining CASI Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Ameriprise sold 1,000 CASI Pharmaceuticals shares in Q2 2022, an estimated $8K.
Ameriprise first reported a position in CASI Pharmaceuticals in Q3 2018 and held it in 15 quarters.
Ameriprise's CASI Pharmaceuticals position peaked at $283K in Q3 2018.
24 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2022.

Based on Ameriprise's 13F filing for Q2 2022, filed 15 Aug 2022.